SHPH Files 8-K on Material Agreement; Details Undisclosed
Ticker: SHPH · Form: 8-K · Filed: Feb 5, 2024 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Feb 5, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.00001, $10,000, $30,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action, undisclosed-terms
TL;DR
**SHPH filed an 8-K about a material agreement, but the crucial details are missing.**
AI Summary
On February 5, 2024, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed an 8-K to report an "Entry into a Material Definitive Agreement" and "Other Events." While the filing indicates a significant agreement, the specific details of this agreement, including names, dollar amounts, or the nature of the transaction, are not disclosed within the provided text. This lack of detail means investors are currently in the dark about a potentially impactful event, which could introduce uncertainty regarding the company's future operations or financial health.
Why It Matters
Investors need to know the specifics of any 'Material Definitive Agreement' to assess its impact on Shuttle Pharmaceuticals' financial position and future prospects. Without these details, it's impossible to evaluate the potential benefits or risks.
Risk Assessment
Risk Level: medium — The filing indicates a material event without providing any specifics, creating uncertainty and making it difficult for investors to assess potential risks or opportunities.
Analyst Insight
A smart investor would await further disclosures from Shuttle Pharmaceuticals Holdings, Inc. regarding the specifics of the 'Material Definitive Agreement' before making any investment decisions, as the current filing lacks critical information to assess impact.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — the registrant filing the 8-K
- February 5, 2024 (date) — date of earliest event reported
- 001-41488 (other) — Commission File Number
- SHPH (other) — Trading Symbol for Common Stock
- The Nasdaq Stock Market LLC (other) — exchange where Common Stock is registered
FAQ
What specific type of 'Material Definitive Agreement' did Shuttle Pharmaceuticals Holdings, Inc. enter into?
The filing states 'Entry into a Material Definitive Agreement' but does not provide any specific details about the nature of the agreement, such as whether it's an acquisition, partnership, or financing deal.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 5, 2024.
What is the trading symbol for Shuttle Pharmaceuticals Holdings, Inc. on The Nasdaq Stock Market LLC?
The trading symbol for Shuttle Pharmaceuticals Holdings, Inc. on The Nasdaq Stock Market LLC is SHPH.
Does the filing disclose any financial terms or dollar amounts related to the 'Material Definitive Agreement'?
No, the filing does not disclose any financial terms, dollar amounts, or other specific monetary details related to the 'Material Definitive Agreement'.
What is the primary business address of Shuttle Pharmaceuticals Holdings, Inc.?
The primary business address of Shuttle Pharmaceuticals Holdings, Inc. is 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
Filing Stats: 1,068 words · 4 min read · ~4 pages · Grade level 14.3 · Accepted 2024-02-05 16:25:13
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $10,000 — following consideration: (i) payment of $10,000 each upon signing the Asset Purchase Ag
- $30,000 — authority for the Invention, and (iii) $30,000 to each Inventor following the Company'
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex10-1.htm (EX-10.1) — 103KB
- 0001493152-24-004927.txt ( ) — 339KB
- shph-20240205.xsd (EX-101.SCH) — 3KB
- shph-20240205_lab.xml (EX-101.LAB) — 33KB
- shph-20240205_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: February 5, 2024 By: /s/ Anatoly Dritschilo Name: Anatoly Dritschilo Title: Chief Executive Officer